01 April 2021
As of today, Sander de Vos will reinforce IME’s management team as Chief Business Officer (CBO). He will be responsible for the worldwide roll-out of our company’s medical electrospinning strategy, based on the ground-breaking MediSpin™XL industrial production platform.
Sander is an accomplished executive with over 15 years of leadership experience across healthcare and biotech commercial and business development positions. Sander has a background in molecular biology, co-developed a molecular diagnostic test for simultaneous detection of tick-borne pathogens and contributed to the development of a vaccine against ticks at the Faculty of Veterinary Medicine of the Utrecht University.
Judith Heikoop, CEO of IME Medical Electrospinning comments:
‘We at IME are thrilled to welcome Sander to our fast-growing team of professionals. Sander clearly brings a wealth of well-needed life science experience into the company, that will certainly be of key value to the further development of our electrospun medical device franchises. Our aim is to become the first partner of choice worldwide for the development of a novel, groundbreaking class of medical devices and pharma products based on nanofibers. Our ever-growing portfolio of customers and partners includes the Medtech and Pharma industry, universities, hospitals and medical institutes.’
Sander de Vos, CBO of IME Medical Electrospinning, adds:
‘With the potential of becoming the global leader in large-scale production of best-in-class nanofiber based medical devices and drug delivery solutions,I’m proud, gratified and delighted to become a member of the IME management team.The company’s technology enables faster and better recovery of tissues and body structures, and therefore IME is uniquely positioned to make a meaningful difference in the lives of patients.’
We are honored with Sander strengthening our team and warmly welcome him to IME.